-
Featured Authors
Archive
- February 2015 (3)
- December 2014 (5)
- November 2014 (2)
- October 2014 (5)
- September 2014 (1)
- August 2014 (3)
- June 2014 (7)
- May 2014 (1)
- March 2014 (2)
- February 2014 (2)
- January 2014 (2)
- December 2013 (3)
- November 2013 (2)
- October 2013 (4)
- September 2013 (3)
- August 2013 (4)
- July 2013 (3)
- June 2013 (2)
- May 2013 (3)
- April 2013 (5)
- March 2013 (2)
- February 2013 (4)
- January 2013 (1)
- December 2012 (2)
- November 2012 (3)
- October 2012 (3)
- September 2012 (3)
- August 2012 (5)
- July 2012 (4)
- June 2012 (7)
- May 2012 (5)
- April 2012 (3)
- March 2012 (4)
- February 2012 (6)
- January 2012 (2)
- December 2011 (2)
- November 2011 (3)
- October 2011 (3)
- September 2011 (5)
- August 2011 (4)
- July 2011 (8)
- June 2011 (16)
- May 2011 (8)
- April 2011 (9)
- March 2011 (14)
- February 2011 (9)
- January 2011 (15)
- December 2010 (7)
- November 2010 (6)
- October 2010 (4)
- June 2010 (1)
- May 2010 (4)
- April 2010 (14)
- March 2010 (4)
- January 2010 (5)
- November 2009 (3)
- October 2009 (1)
- August 2009 (6)
- July 2009 (9)
- June 2009 (9)
- May 2009 (8)
- April 2009 (9)
- March 2009 (9)
- February 2009 (3)
- January 2009 (1)
- November 2008 (1)
Category Archives: Patently BIOtech
Detailed Report Examines the Crucial Role of Patents in Genetic Testing
In The Critical Role of Patents in the Development, Commercialization, and Utilization of Innovative Genetic Diagnostic Tests, Professor Holman argues that advocates for weakening patent protection have fundamental misconceptions on the role of patents in genetic testing. Opponents assume that patents negatively impact patient access to genetic diagnostic testing. They believe that patents inhibit research that could lead to new or improved versions of genetic tests, and that patent holders charge higher prices as exclusive Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: AMP v. Myriad, AMP v. Myriad Genetics, BIOTECH, Biotech Patent, Biotech Patenting, Diagnostic tests, federal patents, Gene Patents, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, Myriad Case, patents, SCOTUS, United States Supreme Court
Tags: AMP v. Myriad, AMP v. Myriad Genetics, BIOTECH, Biotech Patent, Biotech Patenting, Diagnostic tests, federal patents, Gene Patents, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, Myriad Case, patents, SCOTUS, United States Supreme Court
BIO Submits Amicus Briefs in Braintree v. Novel, Gilead v. Natco, and Bristol-Myers Squibb v. Teva Pharmaceuticals
BIO has submitted briefs in three recent cases which could significantly impair drug and biotechnology efforts, urging reconsideration and review from both the Supreme Court and the U.S. Court of Appeals for the Federal Circuit. BIO, in conjunction with PhRMA, submitted an amicus brief to the Supreme Court in Braintree v. Novel, arguing that the majority’s decision creates an unpredictable climate for patent claims. Vacating the prior claim construction precedent which had repeatedly interpreted “a” Read More >
PTO Patent Examinations in the wake of Mayo and Myriad
Biotech patent applicants are finding themselves in uncharted waters. After the Supreme Court’s decisions in Mayo Collaborative Svs. v. Prometheus Labs and Ass’n for Molecular Pathology v. Myriad Genetics, companies have been trying to understand how these decisions will impact the industry. A recent study supported by BIO, in collaboration with Bloomberg BNA and the law firm of Robins, Kaplan, Miller & Ciresi analyzed how Mayo and Myriad have changed patent eligibility for biotechnology. Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: AMP v. Myriad Genetics, BIO, BIOTECH, biotech industry, biotechnology, Biotechnology Industry, Bloomberg BNA, business development, Intellectual Property, IP Protection, Mayo, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, Myriad Case, patent, patent filings, Patents in the Supreme Court, public policy, Stopped at the Threshold, Supreme Court decision, USPTO
Tags: AMP v. Myriad Genetics, BIO, BIOTECH, biotech industry, biotechnology, Biotechnology Industry, Bloomberg BNA, business development, Intellectual Property, IP Protection, Mayo, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, Myriad Case, patent, patent filings, Patents in the Supreme Court, public policy, Stopped at the Threshold, Supreme Court decision, USPTO
BIO Submits Comments on “Myriad” PTO Patent Guidance
On July 31st, BIO, alongside a group of international bioindustry trade associations submitted comments to the United States Patent and Trademark Office regarding their March 4, 2014 Guidance on patent subject matter eligibility. Representing associations from Japan, Australia, Canada, the UK, Germany, Spain, Portugal Belgium, the Netherlands and others, the comments reflect a deep concern among the international community regarding how the PTO is interpreting the Supreme Court’s recent decisions in Mayo v. Prometheus and Read More >
Protecting your IP Overseas
According to the World Intellectual Property Organization (WIPO), nearly 100,000 biotechnology and pharmaceutical patent applications are filed worldwide each year, and the trend appears to be rising. As you’ve likely experienced, filing patent applications can be very complex, with different laws, deadlines and languages requiring highly technical translators for most countries in which you’re seeking protection. As a result, companies seeking IP protection often outsource their domestic and foreign patent filings to service providers to Read More >
